EGFR

EGFR Related Products (738):

By Effects:	Inhibitors (575) Agonists (2) Antagonist (1) Activators (5) Modulators (3) Chemicals (2) Inducers (3) Degraders (19) Controls (6) Substrate (1) Ligands (9)

Cat. No.	Product Name	Effect	Purity

HY-138298A

Trastuzumab deruxtecan	Inhibitor	99.68%
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.

HY-138298

Trastuzumab deruxtecan (solution)	Inhibitor	99.40%
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.

HY-P9977

Amivantamab	Inhibitor	99.90%
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells.

HY-P9921

Trastuzumab emtansine	Inhibitor	99.74%
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer.

HY-P99041

Panitumumab	Inhibitor	99.77%
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer.

HY-P991748

Anti-Human/Mouse Amphiregulin Antibody (AR37)	Inhibitor	99.544%
Anti-Human/Mouse Amphiregulin Antibody (AR37) reacts with human and mouse amphiregulin (AREG) that can block AREG-induced activation of EGFR. Anti-Human/Mouse Amphiregulin Antibody (AR37) can prolong the survival and inhibit the growth of ovarian, breast, and prostate cancer models expressing AREG.

HY-131686A

Ganglioside GT1b (porcine) ammonium	Activator	98%
Ganglioside GT1b (porcine) ammonium is a member of the ganglioside family. Ganglioside GT1b (porcine) ammonium acts as a protective signal against nerve injury-induced spinal synapse elimination. Ganglioside GT1b (porcine) ammonium induces HA synthesis and the phosphorylation of Akt/mTOR in orbital fibroblasts. Ganglioside GT1b (porcine) ammonium enhances porcine oocyte maturation and induces activation of EGFR and ERK1/2 signaling. Ganglioside GT1b (porcine) ammonium is a putative host cell receptor for the Merkel cell polyomavirus. Ganglioside GT1b (porcine) ammonium can be used for the researches of cancer, infection, immunology, endocrinology and neurological disease, such as Thyroid eye disease.

HY-N7424

4,7-Dihydroxycoumarin	Inhibitor	98.25%
4,7-Dihydroxycoumarin is an EGFR inhibitor, estrogen receptor inhibitor, and progesterone receptor inhibitor. 4,7-Dihydroxycoumarin against breast cancer cells with an IC₅₀ velue of 18.36 μg/mL. 4,7-Dihydroxycoumarin can be used for the research of breast cancer.

HY-P9907A

Trastuzumab (anti-HER2)	Inhibitor	99.838%
Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P0221

PACAP (1-38), human, ovine, rat	Inducer	99.99%
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research.

HY-P99275

Patritumab	Inhibitor	99.28%
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.

HY-P10408

Candidalysin	Activator	99.81%
Candidalysin is a cytolytic peptide toxin secreted by the fungus Candida albicans. Candidalysin drives epithelial immune responses by activating the EGFR-MAPK signaling pathway, inducing MMP expression and calcium influx, and regulating the c-Fos transcription factor and MKP1 via p38 MAPK and ERK1/2 respectively. Candidalysin is essential for mucosal and systemic infections, activating NLRP3 to promote inflammatory responses, neutrophil recruitment, and Th17 immunity. Candidalysin activates LDH causing membrane damage and exhibiting cytotoxicity

HY-P9921A

Trastuzumab emtansine (solution)		98.27%
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer.

HY-164992

Trastuzumab vedotin	Inhibitor
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a K_d of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma.

HY-P99507

Zenocutuzumab	Inhibitor	99.9%
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3.

HY-164702

BL-B01D1	Inhibitor	99.65%
BL-B01D1 is a bispecific ADC, which targets EGFR and HER3 through bispecific antibody Izalontamab (HY-P99676), and exhibits cytotoxicity against various cancer cells via inhibition of DNA replication and DNA synthesis by its ADC toxin ED04 (HY-153891). BL-B01D1 can be used in the study of cancer.

HY-N0280

Corosolic acid		99.89%
Corosolic acid (Colosolic acid) isolated from the fruit of Cratoegus pinnatifida var. psilosa, was reported to have anticancer activity. Corosolic acid induces cancer cell apoptosis.

HY-P9968

Nimotuzumab	Inhibitor
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).

HY-P99896

Runimotamab		99.00%
Runimotamab (BTRC-4017A) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99676

Izalontamab	Inhibitor	99.89%
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer.

Name
Email *

	Sorry, but the email address you supplied was invalid.